JAZZ - Jazz Pharmaceuticals plc
| Previous Close | 143.50 |
| Open | 143.08 |
| Bid | 131.00 x 100 |
| Ask | 0.00 x 500 |
| Day's Range | 140.00 - 145.81 |
| 52 Week Range | 130.15 - 184.00 |
| Volume | 976,497 |
| Avg. Volume | 623,890 |
| Market Cap | 8.516B |
| Beta (3Y Monthly) | 1.01 |
| PE Ratio (TTM) | 16.67 |
| EPS (TTM) | 8.47 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 186.22 |
- Simply Wall St.•5 days ago
Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) CEO Salary Justified?
Bruce Cozadd has been the CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) since 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, Read More...
- PR Newswire•11 days ago
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
DUBLIN, Nov. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia, a sleep disorder characterized by chronic and disabling excessive daytime sleepiness (daytime periods of irrepressible need to sleep or daytime lapses into sleep) that is not caused by other conditions known to induce excessive daytime sleepiness. Other symptoms of idiopathic hypersomnia may include prolonged nighttime sleep, long and unrefreshing naps and difficulty waking up from nocturnal sleep or daytime naps.
- PR Newswire•12 days ago
Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting
Nine abstracts, including two oral presentations, accepted for Jazz hematology/oncology portfolio, focusing on leukemia and complications of stem cell transplantation DUBLIN , Nov. 28, 2018 /PRNewswire/ ...
- Thomson Reuters StreetEvents•26 days ago
Edited Transcript of JAZZ earnings conference call or presentation 6-Nov-18 9:30pm GMT
Q3 2018 Jazz Pharmaceuticals PLC Earnings Call
Market Realist•26 days agoWhere Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand
Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017, which reflected ~17% YoY (year-over-year) growth. Defitelio reported net revenues of $111.7 million during the first nine months of 2018—compared to $97.4 million during the same period in 2017, which reflects ~15% YoY growth.
Market Realist•27 days agoJazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.
Market Realist•27 days agoJazz Pharmaceuticals: A Financial Overview in November
Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.
Market Realist•27 days agoJazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9. On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which is ~19% below its 52-week high of $184.00 on June 20.
- Zacks•27 days ago
Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals plc (JAZZ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- PR Newswire•last month
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
DUBLIN , Nov. 9, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, ...
- Investor's Business Daily•last month
IBD 50 Pharma Stock Topples As Cancer Drug Lags Expectations
Jazz Pharmaceuticals stock collapsed Wednesday after the drugmaker missed third-quarter expectations for cancer treatment Vyxeos and cut its guidance for 2018. Shares lost more than 10%.
- Investor's Business Daily•last month
This 99 Composite Rating Pharma Tumbled On Quarterly Sales Lag
Jazz Pharmaceuticals shares crumbled late Tuesday after the top-rated pharma stock missed sales expectations in the third-quarter and issued 2018 guidance that lagged analyst views.
- Zacks•last month
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
- PR Newswire•last month
National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML)
"This is the first new chemotherapy in forty years for adults with specific types of newly diagnosed secondary AML, a particularly aggressive cancer that typically affects older people and has a high mortality rate," said Dr. Nigel Russell, Professor of Haematology, Faculty of Medicine & Health Sciences at the University of Nottingham. "I am pleased that NICE has recognised the value of this medicine for adults with secondary AML.
- Investor's Business Daily•last month
Dow Jones Futures Jump On Election Results; 7 Big Movers On Earnings
Stock futures rose sharply on election results: Democrats won the House but the GOP held the Senate. Seven leaders were big stock market movers on earnings.
- PR Newswire•last month
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at four upcoming investor conferences. Stifel ...
- Motley Fool•last month
Why Jazz Pharmaceuticals plc Stock Is Slumping Today
Jazz's third-quarter earnings missed the mark, causing some investors to hit the exits today.
- Zacks•last month
Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 7.51% and -2.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Jazz: 3Q Earnings Snapshot
The Dublin-based company said it had profit of $2.41 per share. Earnings, adjusted for asset impairment costs and stock option expense, were $3.58 per share. The results topped Wall Street expectations. ...
- PR Newswire•last month
Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results
GAAP Diluted EPS of $2.41 ; Adjusted Diluted EPS of $3.58 Reflects Growth of 11% Total Revenues Increased 14% to $469 Million Xyrem Product Sales Increased 18% to $357 Million Received EU Marketing Authorization ...
- Simply Wall St.•last month
Should We Be Delighted With Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) ROE Of 15%?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
American City Business Journals•last monthHealth Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
- PR Newswire•last month
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
This approval of Xyrem by the FDA marks the first medicine approved to treat cataplexy or excessive daytime sleepiness in children and adolescents with narcolepsy ages seven and older Efficacy and safety ...
